Skip to main content
. 2018 May;10(5):2991–2998. doi: 10.21037/jtd.2018.04.98

Table 3. Efficacy of crizotinib in patients with 21 cases of ALK positive NSCLC positive patients with TP53 gene status.

TP53 gene status CR PR SD PD ORR/% DCR/% PFS (months)
TP53 wild 0 10 1 2 76.92 84.62 10.4
TP53 mutation 0 3 1 4 37.50 50.00 3.3

ALK, anaplastic lymphoma kinase; NSCLC, non-small lung cancer cell; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival.